title: [A multicenter randomized clinical trial of weekly paclitaxel and carboplatin vs three weeks paclitaxel and carboplatin as first line chemotherapy in epithelial ovarian cancer].
abstract: OBJECTIVE
  To compare the efficacy of combination regiments of taxol given weekly plus carboplatin and taxol given every three weeks plus carboplatin. To observe the toxicity of the two regiments. To observe the two-year survival rate in the two groups.
  
  
  METHODS
  Total 125 eligible patients in 13 centers of CGOG were entered into the two arms of this randomized clinical trial, of whom 51 were entered into weekly taxol group and 74 entered into 3 weeks taxol group.
  
  
  RESULTS
  81.6% (102/125) of patients had satisfactory decreasing of CA125 level after optimal cytoreductive surgery and chemotherapy. 86.3% (44/51) of patients is in weekly group and 78.4% (58/74) of patients in three weeks group (P > 0.05). Relapse frequency is 29.7% in every three weeks group and 19.6% in weekly group (P > 0.05). Median interval to relapse is 15.7 months in every three weeks group and 13.6 months in weekly group (P > 0.05). One-year survival rate is 95.2% in every three weeks and 93.9% in weekly group (P > 0.05). Two-year survival rate is 78.7% in every three weeks and 85.3% in weekly group (P > 0.05). Grade III and IV myelosuooression is 45.9% in three weeks group and, 27.5% in weekly group (P < 0.05).
  
  
  CONCLUSIONS
  (1) The two regiments had equal efficacy. (2) Myelosuppression was less frequency in the weekly group than in every three weeks group. (3) Weekly taxol therapy has mild toxicity and is more suitable for the old and feeble patients. Weekly taxol therapy can be conveniently administered in outpatients department.
authors.affiliation: shenkeng@vip.sina.com
authors.forename: Keng
authors.initials: K
authors.lastname: Shen
authors.forename: Meng-da
authors.initials: MD
authors.lastname: Li
authors.forename: You-ji
authors.initials: YJ
authors.lastname: Feng
authors.forename: Ding
authors.initials: D
authors.lastname: Ma
authors.forename: Zi-ting
authors.initials: ZT
authors.lastname: Li
authors.forename: Xing
authors.initials: X
authors.lastname: Xie
authors.forename: Bei-hua
authors.initials: BH
authors.lastname: Kong
authors.forename: Heng
authors.initials: H
authors.lastname: Cui
authors.forename: Lei
authors.initials: L
authors.lastname: Song
authors.forename: Zhi-lan
authors.initials: ZL
authors.lastname: Peng
authors.forename: Li
authors.initials: L
authors.lastname: Li
authors.forename: Ming
authors.initials: M
authors.lastname: Wu
authors.forename: Yi-le
authors.initials: YL
authors.lastname: Chen
authors.forename: Ji-hong
authors.initials: JH
authors.lastname: Lui
authors.forename: Ling-ying
authors.initials: LY
authors.lastname: Wu
authors.forename: Jing-he
authors.initials: JH
authors.lastname: Lang
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D018282:Cystadenocarcinoma, Mucinous / Q000188:drug therapy; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D011446:Prospective Studies; D011506:Proteins / Q000378:metabolism; D016019:Survival Analysis
chemical_list: D047908:Intracellular Signaling Peptides and Proteins; C549756:NBR1 protein, human; D011506:Proteins; D016190:Carboplatin; D017239:Paclitaxel